La situation du cancer en France en 2012 Disponible sur: http://www.ecancer.fr/toutes-les-actualites/7281-publication-du-rapport-sur-la-situation-du-cancer-en- france-en-2012, 2013. ,
Disponible sur: http://www.interpharma.ch/fr/faits-et-statistiques/2830-la-longue-naissance-dun- medicament, 2013. ,
ICH topic E8. General condiserations for clinical trials, 1997. ,
Mémento de la recherche biomédicale portant sur un médicament à usage humain, 2012. ,
Evolution of Clinical Research: A History Before and Beyond James Lind ,
Des cobayes et des hommes Expérimentation sur l'être humain et justice ,
Les Belles Lettres, 2011. ,
Déclaration d'Helsinki de l'AMM -Principes éthiques applicables à la recherche médicale impliquant des êtres humains, 2008. ,
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1), European Journal of Cancer, vol.45, issue.2 ,
DOI : 10.1016/j.ejca.2008.10.026
Guideline on the evaluation of anticancer medicinal products in man, 2012. ,
Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group, Journal of Clinical Oncology, vol.28, issue.11, pp.1963-72, 2010. ,
DOI : 10.1200/JCO.2009.26.3541
??valuation pr??coce des traitements anti-angiog??niques par ??chographie dynamique de contraste, Journal de Radiologie, vol.89, issue.5, pp.549-55, 2008. ,
DOI : 10.1016/S0221-0363(08)71480-X
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria, Clinical Cancer Research, vol.15, issue.23, pp.7412-7432, 2009. ,
DOI : 10.1158/1078-0432.CCR-09-1624
National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 4 Disponible sur: http://evs.nci.nih.gov/ftp1 mélanome cutané en France métropolitaine -Incidence et mortalité 2011, Disponible sur, 2006. ,
A review of human carcinogens???Part D: radiation, The Lancet Oncology, vol.10, issue.8, pp.751-753, 2009. ,
DOI : 10.1016/S1470-2045(09)70213-X
Melanoma--Part 1: epidemiology, risk factors, and prevention, BMJ, vol.337, issue.nov20 1, p.2249, 2008. ,
DOI : 10.1136/bmj.a2249
URL : https://repub.eur.nl/pub/32363/113.pdf
Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure, European Journal of Cancer, vol.41, issue.1, pp.45-60, 2005. ,
DOI : 10.1016/j.ejca.2004.10.016
Sunburns and risk of cutaneous melanoma: does age matter? A comprehensive metaanalysis Ultraviolet radiation and melanoma, Ann Epidemiol. Semin Cutan Med Surg, vol.1830, issue.304, pp.614-27222, 2008. ,
Metaanalysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors Estimating the attributable fraction for melanoma: a meta-analysis of pigmentary characteristics and freckling, Eur J Cancer. Int J Cancer, vol.41127, issue.3210, pp.2040-592430, 2005. ,
Defining the patient at high risk for melanoma, International Journal of Dermatology, vol.92, issue.4, pp.362-76, 2010. ,
DOI : 10.1111/j.1365-4632.2010.04381.x
Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi, European Journal of Cancer, vol.41, issue.1, pp.28-44, 2005. ,
DOI : 10.1016/j.ejca.2004.10.015
Melanoma, Dermatol Clin, vol.30, issue.1, 2012. ,
DOI : 10.1016/B978-1-4160-6643-9.00035-7
Mélanomes cutanés. RéfleXions en Médecine Oncologique, pp.4-5, 2010. ,
The classification of cutaneous melanoma501-13, ix. 40 Final version of 2009 AJCC melanoma staging and classification, Hematol Oncol Clin North Am. J Clin Oncol, vol.2327, issue.336, pp.6199-206, 2006. ,
Epidémiologie du mélanome et application au dépistage précoce. La lettre du cancérologue, pp.81-86, 2009. ,
Early Detection of Malignant Melanoma: The Role of Physician Examination and Self-Examination of the Skin, CA: A Cancer Journal for Clinicians, vol.35, issue.3, pp.130-51, 1985. ,
DOI : 10.3322/canjclin.35.3.130
Early Diagnosis of Cutaneous Melanoma, JAMA, vol.292, issue.22, pp.2771-2777, 2004. ,
DOI : 10.1001/jama.292.22.2771
Clinical recognition of early invasive malignant melanoma., BMJ, vol.301, issue.6759, pp.1005-1011, 1990. ,
DOI : 10.1136/bmj.301.6759.1005
First prospective study of the recognition process of melanoma in dermatological practice434-8. 48. INCa. Mise à jour 2011 des comptes rendus d'anatomopathologie : données minimales à renseigner pour une tumeur primitive. Disponible sur, Arch Dermatol, vol.141, issue.4, 2005. ,
Recommandations pour la Pratique Clinique : Standards, Options et Recommandations 2005 pour la prise en charge des patients adultes atteints d???un m??lanome cutan?? MO Texte court, Annales de Dermatologie et de V??n??r??ologie, vol.132, issue.12, pp.79-85, 2005. ,
DOI : 10.1016/S0151-9638(05)79609-5
The Anticancer Face of Interferon Alpha (IFN-Alpha): From Biology to Clinical Results, with a Focus on Melanoma, Current Medicinal Chemistry, vol.17, issue.29, pp.3327-3363, 2010. ,
DOI : 10.2174/092986710793176393
Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis, Postsurgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial, pp.866-875, 2001. ,
High- and Low-Dose Interferon Alfa-2b in High-Risk Melanoma: First Analysis of Intergroup Trial E1690/S9111/C9190, Journal of Clinical Oncology, vol.18, issue.12, pp.2444-58, 2000. ,
DOI : 10.1200/JCO.2000.18.12.2444
Interférons : utilisation thérapeutique. Traités EMC, 2009. ,
Journal of the National Comprehensive Cancer Network, 2012. ,
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years, J Clin Oncol. Eur J Cancer, vol.1840, issue.112, pp.158-661825, 2000. ,
Timeline: Chemotherapy and the war on cancer, Nature Reviews Cancer, vol.17, issue.1, pp.65-72, 2005. ,
DOI : 10.1056/NEJM199610033351408
The price of innovation: new estimates of drug development costs, Journal of Health Economics, vol.22, issue.2, pp.151-85, 2003. ,
DOI : 10.1016/S0167-6296(02)00126-1
The molecular pathology of cutaneous melanoma, Cancer Biomarkers, vol.9, issue.1-6 ,
DOI : 10.3233/CBM-2011-0164
BRAF: biologie et fonction, Correspondance en Onco- Théranostic, vol.1, pp.14-22, 2012. ,
BRAF and RAS mutations in human lung cancer and melanoma, Cancer Res, vol.62, issue.23, pp.6997-7000, 2002. ,
mutations in metastatic melanoma., Journal of Clinical Oncology, vol.29, issue.15_suppl, 2011. ,
DOI : 10.1200/jco.2011.29.15_suppl.8500
Melanoma: New Insights and New Therapies, Journal of Investigative Dermatology, vol.132, issue.3, pp.854-63, 2012. ,
DOI : 10.1038/jid.2011.421
Mutations of the BRAF gene in human cancer, Nature, vol.7, issue.6892, 2002. ,
DOI : 10.1006/geno.2000.6354
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma, New England Journal of Medicine, vol.363, issue.9, pp.809-828, 2010. ,
DOI : 10.1056/NEJMoa1002011
Survival in BRAF V600???Mutant Advanced Melanoma Treated with Vemurafenib, New England Journal of Medicine, vol.366, issue.8, pp.707-721, 2012. ,
DOI : 10.1056/NEJMoa1112302
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation, New England Journal of Medicine, vol.364, issue.26, pp.2507-2523, 2011. ,
DOI : 10.1056/NEJMoa1103782
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial Dabrafenib and its potential for the treatment of metastatic melanoma, Lancet. Drug Des Devel Ther, vol.3806, issue.82, pp.358-65391, 2012. ,
Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling, Journal of Clinical Oncology, vol.29, issue.22, pp.3085-96, 2011. ,
DOI : 10.1200/JCO.2010.33.2312
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation, Nature, vol.66, issue.7326, pp.973-980, 2010. ,
DOI : 10.1038/nature09626
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation, Nature, vol.21, issue.7326, pp.968-72, 2010. ,
DOI : 10.1038/nature09627
pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial, Lancet Oncol, vol.13, issue.8, pp.773-81, 2012. ,
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial, Melanoma and immunotherapy, pp.782-9547, 2009. ,
DOI : 10.1016/S1470-2045(12)70269-3
Vaccines against advanced melanoma, Clinics in Dermatology, vol.31, issue.2, pp.179-90, 2013. ,
DOI : 10.1016/j.clindermatol.2012.08.005
Traitement du mélanome: immunothérapie cellulaire, Med Ther, vol.6, issue.6, pp.487-93, 2000. ,
Targeting the PD1/PD-L1 axis in melanoma: Biological rationale, clinical challenges and opportunities, Critical Reviews in Oncology/Hematology, vol.89, issue.1, 2013. ,
DOI : 10.1016/j.critrevonc.2013.08.002
What Is the Role of Cytotoxic T Lymphocyte-Associated Antigen 4 Blockade in Patients with Metastatic Melanoma?, The Oncologist, vol.14, issue.8, pp.848-61, 2009. ,
DOI : 10.1634/theoncologist.2009-0028
Immune-checkpoints: the new anti-cancer immunotherapies], Bull Cancer, vol.100, issue.6, pp.601-611, 2013. ,
activity, and immune correlates of anti-PD-1 antibody in cancer, N Engl J Med, vol.366, issue.26, pp.2443-54, 2012. ,
Safety and Tumor Responses with Lambrolizumab (Anti???PD-1) in Melanoma, New England Journal of Medicine, vol.369, issue.2, pp.134-178, 2013. ,
DOI : 10.1056/NEJMoa1305133
relative au soutien apporté par l'Institut national du cancer à l'organisation des essais cliniques en cancérologie. 98, 2006. ,
Les missions d'enseignement, de recherche, de référence et d'innovation (MERRI) Disponible sur: http://www.sante.gouv.fr/les-missions-d-enseignement-de-recherche-de-reference-et-dinnovation-merri .html. Dernière consultation le, 2013. ,